课件：阿卡波糖在2DM治疗中的地位.ppt

* * * Glucose and insulin levels at each time point during a cookie test in the control, acarbose and nateglinide groups. Plasma glucose and insulin levels were not changed at any time point in the controls after 12 weeks. Plasma glucose levels at 30 min during the cookie test were significantly decreased after 12 weeks of treatment with acarbose. Plasma insulin levels at 30 and 60 min were significantly increased after 12 weeks of nategli nide treatment. * * 研究过程中一直给予生长抑素抑制自身胰岛素的分泌，同时给予外源胰岛素维持血糖水平 Nitrotyrosine :硝基酪氨酸 FMD: 血流介导的血管舒张反应 * Background: Several epidemiological studies have shown that postprandial hyperglycemia is associated with an increased risk of cardiovascular disease (CVD). The present study was conducted in order to compare the effects of acarbose and glimepiride treatment on serum lipoprotein profiles in patients with type 2 diabetes. Methods: A total of 37 patients with newly diagnosed type 2 diabetes were studied. The patients were assigned randomly to treatment for 12 weeks with either acarbose (n=13, 100 mg×3/day, group A), glimepiride (n=13, 2 mg/day, group G) or diet only (n=11, group D). Lipid and lipoprotein profiles before and after each treatment were evaluated. Results: A significant reduction in the net electronegative charge of low-density lipoprotein (emLDL) was observed in group A (?1.8, Pb0.01), whereas no significant change in emLDL was observed in groups G and D. In group A, small VLDL and very small LDL levels were also decreased significantly (P0.05). The change in emLDL levels correlated significantly with changes in very small LDL (r=0.751, P0.01) and oxidized LDL levels (r=0.623, P0.05). Conclusion: These results suggest that measurement of serum emLDL may be a sensitive and clinically useful marker for determining qualitative lipoprotein abnormalities in diabetes, and that acarbose treatment lowers CVD risk by decreasing production of emLDL * * * 目的：比较T2DM患者在使用磺脲+双胍的基础上，加用那格列奈或阿卡波糖对代谢的作用。研究主要终点为何种治疗方案降低PPG更有效，次要终点为评估何种治疗方